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Abstract 
ANKHD1 is differentially expressed in human 
cancers, and potentially regulates multiple cellular 
functions and participates as a scaffold for protein-
protein interactions through its ankyrin-repeat 
domains. Recently, studies have indicated that 
ANKHD1 is involved in the regulation of important 
biological process that participate in the malignant 
phenotype, including cell cycle progression, 
proliferation, clonogenicity and migration. The 
present review on ANKHD1 contains data on 
DNA/RNA, protein encoded and where the gene is 
implicated. 
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Identity 
Other names: MASK, VBARP, PP2500 
HGNC (Hugo): ANKHD1 
Location: 5q31.3 
DNA/RNA 
Description 
The entire ANKHD1 gene is about 147 Kb (start: 
139781399 and end: 139929163 bp; orientation: plus 
strand). The ANKHD1 gene encodes for 4 transcript 
variants. The transcript variant 1 (start: 139781399 
and end: 139919441 bp; orientation:  
plus strand; 34 exons; mRNA: 8233 bp) is the 
longest transcript and encodes the isoform 1 (2542 
aa protein). The transcript variant 2 (start: 
139781399 and end: 139852062 bp; orientation: plus 
strand; 11 exons; mRNA: 2161 bp) uses an alternate 
in-frame splice site in the 5` coding region, lacks 
several exons, uses an alternate 3` terminal exon and 
encodes the isoform 2, which is shorter and presents 
a distinct C-terminus compared to isoform 1 (616 aa 
protein). Transcript variant 3 (start: 139781399 and 
end: 139852062 bp; orientation: plus strand; 11 
exons; mRNA: 2194 bp) lacks several exons, uses an 
alternate 3` terminal exon and encodes the isoform 3 
that also has a distinct C-terminus compared to 
isoform 1 (627 aa protein). Transcrit variant 4 (start: 
139781399 and end: 139852062 bp; orientation: plus 
strand; 10 exons, mRNA: 2084 bp) also lacks several 
exons, uses an alternate 3` terminal exon, encodes 
the isoform 4 that has a distinct C-terminus 
compared to isoform 1 and is the shortest of all 
isoforms (581 aa protein). Additionally, ANKHD1-
EIF4EBP3 is a readthrough transcript involving 
ANKHD1 and EIF4EBP3 genes, which encodes a 
protein that contains multiple ankyrin repeats, single 
KH-domain and a C-terminus with a portion from 
the EIF4EBP3 gene (start: 139781399 and end: 
139929163 bp; orientation: plus strand; 36 exons, 
mRNA: 8349 bp; protein: 2617 aa). Data searched at 
GenBank NCBI 
(http://www.ncbi.nlm.nih.gov/genbank/) and UCSC 
Genome Browser (https://genome.ucsc.edu/). 
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Protein 
Description 
The ANKHD1 protein has 4 isoforms. Isoforms 2, 3 
and 4 are smaller and less characterized than isoform 
1. Isoform 1 of ANKHD1 protein consists of 2542
amino acids with a molecular weight of 270 kDa, has 
20 ankyrin repeats distributed in two blocks and a K 
homology (KH) domain in the C-terminal region. 
The schematic representation of ANKHD1 protein 
(isoform 1) is illustrated in Figure 1. 
Expression 
Ubiquitous. 
Localisation 
ANKHD1 is predominantly found in the cytoplasm 
(Figure 2). 
Function 
The ANKHD1 protein contains 20 ankyrin repeats, 
which are highly conserved structures. The presence 
of ankyrin repeats domains suggests that  
this protein integrates multiple signaling pathways 
and participates as scaffold for protein-protein 
interactions (Jernigan and Bordenstein, 2015). A 
large part of the knowledge regarding the functions 
of ANKHD1 was obtained by experiments using its 
orthologous protein Mask (multiple ankyrin repeats 
single KH domain). In Drosophila, Mask acts in the 
signal transduction pathway mediated by Cws 
(Corkscrew; orthologous of SHP2) (Smith, et al., 
2002), participates in the Hippo signaling pathway 
activation through its association with Yki (Yorkie, 
orthologous of YAP1) (Sidor, et al., 2013, Sansores-
Garcia, et al., 2013) and potentially regulates Hop 
signaling pathway (Hopscotch, orthologous of JAK) 
(Muller, et al., 2005). 
In humans, ANKHD1 associates with SHP2, 
however the biologic consequence of this protein 
interaction remains indeterminate (Traina, et al., 
2006). ANKHD1 and YAP1 interaction has also 
been confirmed in human cells (HEK293 and 
DU145 cells) and modulates the Hippo signaling 
pathway activation, proliferation and cell cycle 
progression (Sidor, et al., 2013, Sansores-Garcia, et 
al., 2013, Machado-Neto, et al., 2014). 
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ANKHD1 interacts with SIVA and modulates the 
microtubule dynamics, cell proliferation and 
migration of human leukemia cells (Machado-Neto, 
et al., 2015). In addition, ANKHD1 modulates p21 
(CDKN1A) expression and cell cycle progression in 
multiple myeloma cells (Dhyani, et al., 2015, 
Dhyani, et al., 2012). In NT2 cells, inhibition of the 
small isoform of ANKHD1 that lacks the KH 
domain (also designed as VBARP; isoform 3) 
triggered caspase-3/7 activation (Miles, et al., 2005), 
however no similar effect on apoptosis was observed 
in the other cell lines inhibited for all other 
ANKHD1 isoforms (Machado-Neto, et al., 2014, 
Machado-Neto, et al., 2015, Dhyani, et al., 2012). A 
potential model for ANKHD1 cellular functions and 
protein interactions is summarized in Figure 3. 
Homology 
ANKHD1 shares high homology with ANKRD17 
(ankyrin repeat domain 17), both orthologous 
proteins to Mask protein from Drosophila. 
ANKHD1 also shares high homology among 
different species (Table 1). 
Mutations 
Somatic 
Recurrent mutations in the ANKHD1 gene are rare, 
180 substitution missense, 13 substitution nonsense, 
58 substitution synonymous, 1 insertion frameshift 
and 1 deletion frameshift mutations are reported in 
COSMIC (Catalogue of somatic mutations in cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). 
Implicated in 
Leukemia 
Note 
ANKHD1 was reported as highly expressed in 
leukemia cell lines and in primary bone marrow 
samples from patients with acute myeloid leukemia 
and acute lymphoid leukemia (Traina, et al., 2006). 
Interestingly, ANKHD1 silencing reduced cell 
proliferation, clonogenicity, migration and 
tumorigenesis of leukemia cells (Machado-Neto, et 
al., 2015). 
Multiple myeloma 
Disease 
Multiple myeloma cell lines and primary plasma 
cells from myeloma multiple patients presented a 
high expression of ANKHD1 (Dhyani, et al., 2012). 
In multiple myeloma cell lines, ANKHD1 inhibition 
resulted in a delay in cell cycle progression and 
lower cell proliferation, clonal growth, migration 
and tumor formation (Dhyani, et al., 2015, Dhyani, 
et al., 2012). 
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Prostate cancer 
Note 
High expression of ANKHD1 was observed in 
prostate cancer cell lines (Machado-Neto, et al., 
2014). Using the siRNA approach, ANKHD1 
silencing reduced proliferation, tumor formation, 
and cell cycle progression in prostate cancer cells 
(Machado-Neto, et al., 2014). 
Breast cancer 
Prognosis 
In two independent cohorts of breast cancer patients, 
high expression of ANKHD1 was associated with 
worsened outcomes (Sansores-Garcia, et al., 2013). 
To be noted 
Although ANKHD1 presents high homology with 
ANKRD17 (both orthologous proteins of Mask), the 
Ankrd17 knockout mice presents embryonic 
lethality (Hou, et al., 2009), indicating that these 
proteins do not play redundant functions. Another 
interesting point is that, accordingly to current data, 
ANKHD1 participates in cell proliferation and cell 
cycle progression in different neoplastic cells; 
however the ANKHD1-interacting proteins appear 
to vary, depending on the cellular context. 
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